Together we will beat cancer

Donate

Better together: improving brain tumour treatment

We’ve helped double brain tumour survival over the past 40 years. Now, researchers are combining some of our most successful drugs, temozolomide and PARP inhibitors, to make glioblastoma treatment more effective.

Read More

Women in science: Cancer research pioneers – part 1

As our 20th anniversary year draws to a close, we’re celebrating some of the pioneering women who have contributed to impactful cancer research and paved the way for even more.

Read More

Our most important cancer research stories of 2022

This year has been full of research, advances and people worth celebrating. Here are some of our biggest stories from the past 12 months. 

Read More

NICE doesn’t recommend olaparib for patients with certain prostate cancers

NICE does not recommend olaparib (Lynparza) for people with a type of advanced prostate cancer, as the treatment is not deemed cost-effective

Read More

COVID-19 vaccine and cancer – latest updates

Recently, news of a COVID-19 vaccine has dominated headlines. We’ve summarised all the information that is out there, with rolling updates, in our new vaccine blog post.

Read More

The award-winning team transforming breast cancer treatment

We spoke to Professor Andrew Tutt about how you build a successful scientific team, the importance of translation and why you always need a touch of humbleness…

Read More

Latest episode of our podcast for cancer researchers

Cancer Research Matters provokes conversation around cancer science, how it shapes our understanding of the disease and the challenges we face as we develop therapies

Read More

Diving into our role in 50 top cancer drugs

To mark 20 years since the merger of the Cancer Research Campaign and the Imperial Cancer Research Fund, we’ve delved into the research of the charities’ that led to many of the drugs in use today.

Read More

Introducing our new podcast for researchers

Cancer Research Matters provokes conversation around cancer science, how it shapes our understanding of the disease and the challenges we face as we develop therapies.

Read More

Reflections from our chief scientist: The rise of the whole organism

Chief scientist Karen Vousden, contemplates the advances coming from cell biology and genomics and why the new frontiers of cancer research require a systems biology approach.

Read More